Prostate cancer (PCa) is considered to be a frequently diagnosed cancer in males with high mortality worldwide, but the molecular mechanism responsible for prostate tumorigenesis and progression remains unclear. Increasing evidence has shown that microRNAs (miRNAs) play an important role in PCa. In this review, we focus on the current advances about the role of miRNAs in regulating tumorigenesis and progression of PCa, mainly in suppressing or promoting PCa growth and metastasis, and maintaining the pluripotency of PCa stem cells (PCSC). More studies on miRNAs will provide a better understanding of their regulatory mechanisms in PCa.
INTRODUCTION
Prostate cancer (PCa) is currently considered to be the second most frequently diagnosed cancer and the sixth cause of cancer death in males in the United States. Statistics shows that PCa accounts for 14% (903 500) of the total new cancer cases and 6% (258 400) of the total cancer deaths in males in 2008. 1 The serum levels of prostate-specific antigen (PSA) and other tumor markers such as Bcl-2 are recently used for diagnosis of PCa. 2, 3 However, it has been criticized to use PSA alone as a biochemical monitor for its poor positive predictive value. 4 In addition, traditional treatments such as radical prostatectomy and radiotherapy with or without adjuvant androgen deprivation have only a modest benefit to advanced PCa because of the development and acquisition of castration resistance PCa (CRPC) and eventually leading to metastasis. 5, 6 Therefore, investigations are ongoing to uncover the mechanisms associated with the tumorigenesis and progression of PCa in more details in order to develop novel therapeutics. Among these investigations, specific microRNAs (miRNAs) appear to be crucial molecules that can regulate the growth, castration resistance and metastasis of PCa and emerge as attractive targets for potential clinical applications including diagnosis, treatment and prognosis in the future.
MiRNAs are small, noncoding RNAs that modulate expression of specific genes at post-transcriptional levels. Through interactions with the 3 0 untranslated region (3 0 UTR) of mRNAs, a given miRNA leads to the degradation of its target mRNAs or suppression of its protein translation. Evidences have shown that miRNAs are involved in multiple biological processes and also tightly correlated with tumorogenesis. 7, 8 The change of miRNA profiling was found in several cancers including PCa. [9] [10] [11] [12] [13] [14] Studies on PCa so far have demonstrated that some miRNAs can act as either an oncogene or a tumor suppressor depending upon the context. 15, 16 In addition, the expression and functions of some miRNAs are well-correlated with the presence of androgen in PCa, meaning that they may be androgen-inducible. [17] [18] [19] [20] [21] Here in this review, we focus on a series of PCa-related miRNAs and give an overview how they regulate the process of tumorigenesis, castration resistance, stemness and metastasis of PCa (Table 1) .
MIRORNAS AS SUPPRESSORS OF PCA GROWTH AND METASTASIS

MiR-15a and miR-16
The miR-15a-miR-16-1 cluster is found to be associated with the regulation of multiple oncogenes such as Bcl-2, cyclin D1 and Wnt3a, 22 which promote several tumorigenic features in untransformed prostate cells including survival, proliferation and invasion. Restoration of miR-15a and miR-16 expression results in growth arrest, apoptosis and marked regression of prostate tumor xenografts in vivo. 22 By investigating the interactions between PCa cells and their tumor-supportive stromal cells, miR-15a and miR-16 are also found to be downregulated in fibroblasts surrounding the prostate tumors. 23 It has been further demonstrated that FGF-2 (fibroblast growth factor 2) and its receptor FGFR-1 can be repressed by miR-15a and miR-16 as targets. These two molecules are well-known to play important roles in both stromal and tumor cells to enhance cancer cell survival, proliferation and migration. Induction of cell-cycle arrest 29 Improvement of androgen sensitivity 30 E2F2, Cyclin D2 29 Lin 28 [32] [33] [34] c-Myc 36, 39 Tumor suppressor Transcriptional repression 30, [32] [33] [34] Let-7c 21q21.1 Double-negative feedback regulation of let-7 family process [32] [33] [34] Indirect regulation of AR expression 39 Repression of self-renewal in PCSC are shown to be involved in tumor progression such as proliferation and epithelial-mesenchymal transition (EMT). 28 Recently, Dong et al. 29 found that ectopic expression of let-7a downregulates the expression of E2F2 and Cyclin D2 through directly binding with their 3
0 UTR and induces cell-cycle arrest. Expression of let-7a is repressed in PCa cell lines as well as in patient samples. Another member, let-7c, is also downregulated in PCa cells, especially in CRPC cells. Its impairment enhances the growth of androgen-sensitive PCa cells under androgen-deprived conditions in vitro. 30 Along with the downregulation of let-7c, Lin28, a post-transcriptional regulator of let-7c, is upregulated in PCa cells as well as in clinical specimens. 30, 31 Lin28 can bind to the terminal loop of the loop-stem structure in the precursors of let-7 family miRNAs so that it acts as a negative regulator at the posttranscriptional level and impede the maturation of let-7 family. 32, 33 On the other hand, let-7 targets the Lin28 mRNA for post-transcriptional repression as well. 34 This double-negative feedback loop is shown to be involved in the regulation of c-Myc, 35, 36 which is also a target of let-7c. [37] [38] [39] Nadiminty et al. 39 have further demonstrated that through this feedback loop, let-7c can work as a key regulator of expression of androgen receptor (AR) by targeting its transcription ( Figure 1 ). These findings together suggest that let-7c plays a crucial role in the regulation of androgen signaling and is a potential therapeutic molecule for PCa.
MiR-133
Overexpression of miR-133a/b is found to inhibit cell proliferation and induce cell apoptosis in several types of cancers. [40] [41] [42] [43] [44] Recently, miR-133a/b is detected at a limited expressional level in hormone-insensitive PCa cell lines PC3 and DU145. Forced expression of miR-133 reduces cell proliferation, migration and invasion in these two cells via targeting EGFR (epidermal growth factor receptor). 45 In addition, purine nucleoside phosphorylase (PNP), which is frequently overexpressed and involved in cell proliferation and invasion in bladder cancer, 46 is also reported to be regulated by miR-133a and miR-1 in PCa. 47 On the other hand, miR-133b is found to be involved in the regulation of cell death through death receptor-mediated apoptosis in HeLa and PC3 cells. 48 Overexpression of miR-133b sensitizes these cells to undergo TNFa (tumor necrosis factor-a)-induced cell death and pro-apoptotic responses to TRAIL (TNF-related apoptosis-inducing ligand) or Fas/CD95. Meanwhile, Fas apoptosis inhibitory molecule (FAIM), an anti-apoptosis gene which is widely expressed in B cells with a protective effect against Fas/CD95-mediated apoptosis, 49 is shown to be regulated by miR-133b directly as a target. 48 These results reveal an essential role for miR-133 in inducing apoptosis against tumorigenesis. Mutual negative feedback loop in regulation of the maturation of let-7 miRNAs and the AR expression. The pre-let-7 family are first transcribed from let-7 family genes and processed by Drosha in the nucleus. After exported to the cytoplasm, pre-let-7 family can be further processed by Dicer into mature miRNAs or failed to produce the mature miRNAs by Lin28 blocking. Lin28 is regulated by c-Myc at a transcriptional level and both of them are the targets of let-7 at post-transcriptional levels. In addition, the expression of AR is associated with c-Myc and repressed by let-7.
Mediated by let-7, a mutual negative feedback loop is built among these genes and the crumble of the feedback loop induces the underexpression of let-7 and promotes the progression of PCa.
MiR-203 and miR-205
MiR-203 is often shown to be silenced in different malignancies including PCa. [50] [51] [52] In brain (DU145) or bone metastatic (PC3) PCa cell line, overexpression of miR-203 is sufficient to inhibit cell proliferation, migration and invasiveness and to reverse the phenotype of EMT. 52 Genes that are involved in these events mentioned above are identified as targets of miR-203 such as Runx2, CKAP2, ZEB2 and survivin etc. 52, 53 These results indicate that miR-203 can be a potentially novel prognostic marker and an attractive therapeutic molecule for metastatic PCa. In addition, miR-205 is also found to be a metastasis-related miRNA and downregulated in PCa. 54 Recently, hypermethylation of the miR-205 locus is reported as a critical mechanism for the epigenetically induced repression of miR-205 transcription and is associated with recurrence of PCa. 55 Restoration of miR-205 expression in PCa cells induces a mesenchymal-epithelial transition (MET) marked by upregulation of E-cadherin and reduction of cell invasion. Several cell invasive markers such as N-chimaerin, ErbB3, E2F1, E2F5 and protein kinase Ce (PKCe) are shown as targets of miR-205. 56 Further studies have shown that miR-205 is regulated by p63, whose inhibitory effect on EMT markers such as ZEB1 and vimentin is achieved via miR-205. Restoring p63 and/or miR-205 expression significantly inhibits the metastasis from prostate to the lung. 57 In addition, miR-205 is reported to prevent PCa cells from invading into interstitial spaces by preserving the tissue integrity of the basement membrane. 58 Meanwhile, miR-205 appears to have the capability to induce apoptosis and cell-cycle arrest. Through repressing the expression of anti-apoptosis genes Bcl-w and E2F6, miR-205 promotes chemotherapeutic agents-induced apoptosis in PCa cells. 59 More recently, both miR-203 and miR-205 are shown to coordinate with miR-130a to regulate the expression of key components of the mitogen-activated protein kinase (MAPK) and AR signaling pathways. 60 Both pathways are crucial for the development of primary PCa and the induction of CRPC. Restoration of the expression of three miRNAs in an AR-positive PCa cell line LNCaP resembles the effect of androgen deprivation and inhibits cell proliferation by inducing apoptosis and cell-cycle arrest. 60 These results demonstrate that miR-203 and miR-205 exert a tumorsuppressive effect by suppressing EMT and impairing cell growth, indicating that both two miRNAs are attractive therapeutic candidates for PCa.
MiR-200 family It has been well-known that EMT underlies cancer cell invasion and metastasis. Several transcription repressors, which regulate the loss of epithelial markers, have been identified to be associated with these processes including zinc-finger E-box binding homeobox (ZEB) 1 and 2. 61, 62 Recent studies have shown that overexpression of platelet-derived growth factor-D (PDGF-D) in PCa cell line PC3 represses the expression of miR-200b. Meanwhile, miR-200 family is found to regulate the EMT by targeting ZEB1 and ZEB2, so that the acquisition of the EMT phenotype in PC3, which can be induced by PDGF-D, is in part, if not all, a result of miR-200 family repression and subsequent overexpression of ZEB1 and ZEB2. 63 In addition to the PDGF-D, TGF-b1 (transforming growth factor b-1) can induce EMT in PCa as well as in BPH (benign prostate hyperplasia). Restoration of miR-200 family expression prevents the initiation of EMT in BPH cells, which is induced by TGF-b1, by repressing the expression of the transcription factors described above. 64 Underexpression of miR-200 family also upregulates the expression of SNAI2/Slug, a major regulator of mesenchymal differentiation and EMT initiation in BPH cells. 65 Further studies indicate that Slug is a direct repressor of miR-200 and miR-1 transcription. Meanwhile, the expression of Slug itself is regulated by miR-200/miR-1 directly at a post-transcriptional level so that Slug and miR-200/miR-1 compose a self-reinforcing regulatory loop. 66 In addition, miR-1 is a promising candidate marker for prognosis of PCa. 67 The aberration of this homeostasis, which occurs due to the underexpression of miR-200/miR-1, leads to the amplification of EMT in PCa. 66 Furthermore, reduction of miR-200c is found to lead to docetaxel resistance which is mediated by EMT. 68 These results indicate that miR-200 family can become a promising molecule for the prediction of relapse 69 and the treatment of PCa by suppressing EMT.
MiR-34 family Among this family, miR-34a is well-known as a target of the tumor suppressor p53 and is reported to be frequently silenced in several types of cancers including PCa. Mechanistic investigations reveal that in primary prostate carcinomas aberrant CpG methylation of the miR-34a promoter is frequently displayed and thus its transcription is subsequently silenced. 70 In addition, it is demonstrated that some topoisomerase inhibitors such as doxorubicin and camptothecin (Campt) can induce the phosphorylation and activation of p53, which in turn upregulates the expression of both miR-34a and miR-34c. 71 Interestingly, upregulation of miR-34a expression is AR-dependent and is blocked in AR-negative PCa cell lines such as PC3 and DU145 or by AR knockdown. Meanwhile, the cooperation between miR-34a and miR-34c may play a crucial role in AR-dependent p53-mediated apoptosis in PCa. 71 On the other hand, AR itself has been shown to be a direct target of miR34a. Overexpression of miR-34a in PCa cell line represses AR expression concomitant with the decrease of PSA and Notch-1 expression. In primary prostate carcinomas with miR-34a epigenetic silencing, the activation of AR can be reversed by 3,3 0 -diindolylmethane by Bio Response (abbreviated as BR-DIM), which has an effect on demethylation of miR-34a promoter and in turn restores its transcription. 72 Moreover, Lodygin et al. 70 have reported that forced expression of miR-34a in vitro induces a G1 cell-cycle arrest, senescence and apoptosis partly by targeting CDK6 in PCa cells. Several anti-apoptosis genes (for example, HuR, Bcl-2 and SIRT1) are also identified as a direct target of miR-34a. Repressing the expression of these genes by ectopic expression of miR-34a can attenuate the resistance to paclitaxel in PC3 PCa cells. 73 Another important target of miR-34a in PCa is c-Myc. The repression of c-Myc impairs the activity of c-Myc-Skp2-Miz1 transcriptional complex and in turn represses RhoA, a regulator of cell migration and invasion. 74 These findings indicate that miR-34a can inhibit invasion of PCa by repressing RhoA through c-Myc. 75 In addition to miR-34a, miR-34b and miR-34c are also able to regulate c-Myc expression by targeting its 3 0 UTR. 76 Overexpression of c-Myc in PCa upregulates the expression of uiquitin-specific protease 2a (USP2a) and in turn inactivates p53 so that the expression of several miRNAs downstream including miR-34b and miR-34c can be undermined. 76 Besides p53 inactivation, miR-34b appears to be silenced through CpG hypermethylation in PCa. 77 Meanwhile, DNMTs (DNA methyltransferases) and HDACs (histone deacetylases) are confirmed as targets of miR-34b, which results in a positive feedback loop to active chromatin modifications. MiR-34b inhibits cell proliferation and EMT by targeting AKT and in turn reducing the expression of several mesenchymal markers such as Vimentin, N-cadherin and Snail. 77 MiR-34c appears to negatively regulate E2F3 and BCL-2 and is associated with migration and invasion in PCa. 78 These findings provide insight into the role of miR-34 family as tumor suppressor in regulation of proliferation, apoptosis and invasiveness in PCa.
MiR-143 and miR-145 As a tumor suppressor gene, miR-143 plays important roles in carcinogenesis in various tissues. [79] [80] [81] In PCa, miR-143 is shown to regulate cell proliferation and migration, and enhance the microRNAs in prostate cancer Y-X Fang and W-Q Gao response of PCa to docetaxel by targeting KRAS and subsequently targeting EGFR/RAS/MAPK pathway. 82 In addition to KRAS, ERK5 (extracellular signal-regulated kinase 5) 83 and KLKs (Kallikreinrelated peptidases) 84 are also targets of miR-143. ERK5 functions as a response to growth factors via activation of tyrosine kinase and its downstream MAPK cascade to promote cell growth and proliferation. 83 KLKs belong to a serine proteases family and are involved in miR-143-induced cell growth inhibition. 84 In addition, based on studies on bone metastasis of PCa, miR-143 and miR-145 are together downregulated significantly in metastatic samples. Reexpression of these two miRNAs restores the expression of E-cadherin and simultaneously represses fibronectin expression in PC3 cells and thus exerts a less invasive phenotype. 85 MiR-145 is another tumor suppressor that is often observed to be downregulated in both PCa cell lines (for example, PC3, DU145 and LNCaP) and primary prostate carcinomas. 86 Overexpression of miR-145 in PC3 leads to increased apoptosis concomitant with cell-cycle arrest in G2/M phase. It is shown that miR-145 regulates apoptosis by targeting pro-apoptotic gene TNFSF10, a member of the family of TRAIL molecules. 87 Hypermethylation at the promoter region of miR-145 appears to obstruct the binding of p53 to its response element upstream of miR-145, which closely correlate with the miR-145 silencing. 88 By screening targets of miR-145, fascin homolog 1 (FSCN1), a member of the fascin family of actin-binding proteins, has been shown to be a direct target gene of miR-145.
89 FSCN1 plays a critical role in cell migration, motility, adhesion and cellular interactions and is correlated with tumorigenesis and metastasis. 90, 91 In addition to FSCN1, switching B-cell complex 70 kDa subunit (SWAP70), an F-actin-binding protein involved in activating B-cell transformation, appears to be a target of miR-145 as well. Repressing SWAP70 by miR-145 leads to a significant inhibition on cell migration and invasion in PCa cell lines. 92 Since downregulation of miR-143 and miR-145 frequently occurs in PCa, both of them and their targets may become novel biomarkers for early diagnosis, stage discrimination and bone metastasis prediction of PCa.
Other tumor suppressing miRNAs in regulation of PCa Some other miRNAs are more recently found to function as tumor suppressors during the progression of PCa. MiR-31 expression is reduced by hypermethylation at its promoter region and directly regulates AR expression through interaction with a binding site harbored at the coding region of AR. Further studies demonstrate that restoration of miR-31 expression induces a cell-cycle arrest of PCa by a mutual repression between miR-31 and AR. 93 MiR-124 is another tumor suppressor to directly repress AR expression and inhibit cell growth of PCa. Expression of miR-124 is reduced by DNA methylation in PCa. 94 In addition, miR-17-5p is reported to repress the expression of p300/CBP-associated factor, a coactivator of AR, to modulate the transcriptional activity of AR and inhibit cell growth in cultured PCa cells. 95 
MIRNAS PROMOTING PCA TUMOROGENESIS AND METASTASIS
MiR-21 AR is a ligand-dependent transcription factor 96 and plays pivotal roles in facilitating proliferation, cell survival and androgenindependent growth of PCa. 97, 98 Recent evidence has shown that AR can induce the transcription of several miRNAs. 17 A highly conserved androgen response element (ARE) is proven to be presented in promoter regions of AR-inducible miRNAs, such as miR-21, to recruit AR to the promoter and in turn trigger their transcription (Figure 2 ). Though miR-21 is an AR-regulated miRNA and its expression is dramatically high in CRPC, 17 the AR-mediated transcription of miR-21 is seen at similar levels between ADPC (androgen-dependent PCa) and AIPC (androgen-independent PCa) cells. 18 This result indicates that AR/miR-21 pathway is activated during both androgen-dependent and -independent stage of PCa. It also indicates that in addition to AR, other factors may also be involved in the regulation of miR-21 expression. Fujita et al. 99 found that several conserved enhancer elements such as AP-1 (activation protein 1) and STAT 3 (signal transducer and activator of transcription 3) binding sites are included in miR-21 promoter region. AP-1 appears to be associated with the progression and recurrent, 100 and STAT-3 contributes to the anti-apoptosis and cell survival in PCa. 101, 102 Recently, Yang et al. 103 further found that IFN (interferon) could induce miR-21 expression in a STAT-3-dependent way. Silence of STAT-3 and NF-kB blocks IFN-induced binding of p65 to the miR-21 promoter, which indicates that miR-21 is a novel target and a pivotal feedback regulator for IFN-induced apoptosis. 103 In addition, the chromosome area of miR-21 gene itself (17q23.1) is an amplified area in several types of cancer including PCa. 104 All these mentioned data support miR-21 as an onco-miRNA.
On the other hand, overexpression of miR-21 downregulates its downstream targets programmed cell death 4 (PDCD4), a tumor suppressor which is associated with apoptosis, and promotes cell transformation. 105 A putative miRNA response element (MRE) is located in the 3 0 UTR of PDCD4. Deletion or mutations in the MRE abrogates the inhibition of PDCD4 expression by miR-21, which indicates that this MRE region is critical for miR-21 regulation. 105 Recent studies have further revealed that miR-21 is involved in mediating the chemoresistance via PDCD4 regulation in an AIPC cell line PC3. Forced expression of miR-21 impairs while silence of miR-21 sensitizes the PC3 to docetaxel, which is consistent with the decreased or restored expression of PDCD4, respectively. 106 However, in another group's studies, miR-21 knockdown appears to be insufficient to modulate the expression of PDCD4 and PTEN though both genes are identified as targets of miR-21. Furthermore, overexpression of miR-21 alone has a limited effect on enhancing cell proliferation and invasion in PCa. 107 However, other studies demonstrate that in DU145, PTEN targeted downregulation due to overexpression of miR-21 increases the expression of hypoxia inducible factor 1 alpha (HIF-1a) and vascular endothelial growth factor (VEGF), as well as the activation of AKT and ERK1/2, which synergistically leads to tumor angiogenesis. 108 Among these four genes, inhibition of HIF-1a alone impairs the effect of miR-21 on inducing tumor angiogenesis, indicating that HIF-1a, a key downstream of miR-21, is essential for miR-21-upregulated angiogenesis. 108 In addition, basal protein B-cell translocation gene 2 (BTG2) is another important target of miR-21. 109 It is commonly accepted that PCa derives from those basal compartments, which ectopically express luminal markers. 110, 111 During this process, BTG2 loss is associated with a change of normal prostate basal cells to cells expressing luminal markers concomitant with the appearance of EMT feature. Thus, overexpression of miR-21 decreases the BTG2 levels and in turn initiates the acquisition of luminal markers and EMT in PCa. 111 Another invasion-related gene regulated by miR-21 is RECK, a matrix metalloproteinase inhibitor. Restoration of RECK expression by neutralizing miR-21 represses the matrix metalloproteinase levels and reverses the invasive phenotype. 112 These results demonstrate the function of miR-21 as an onco-miRNA on regulating EMT and anti-apoptosis, and indicate a promising diagnosis/prognosis application for PCa.
MiR-32 and miR-148a
Both miR-32 and miR-148a are identified as androgen-regulated miRNAs and give a significant growth advantage for LNCaP, a hormone-sensitive PCa cell line, when forced expression of either of them. Further studies reveal that in LNCaP cells, the function of these two miRNAs on stimulating proliferation is different as miR-32 reduced cell apoptosis while miR-148a enhanced cell growth. 16, 113 In addition, Jalava et al. 16 have reported that BTG2 is a target of both miR-32 and miR-148a besides miR-21. Significant upregulation of miR-32 and relevant reduction of BTG2 are confirmed in CRPC specimens compared with BPH specimens. Overexpression of miR-32a and/or miR-148a also represses expression of phosphoinositide-3-kinase interacting protein 1 (PIK3IP1), a membrane protein that induces cell apoptosis, 114 as well as another apoptotic activator Bim. 115 In hormone-refractory PCa cell lines DU145 and PC3, however, the expression level of miR-32 did not change but that of miR-148a is decreased as compared with LNCaP or PrEC normal human prostate epithelial cells. 15 Re-introduction of miR-148a not only inhibits the cell growth, migration and invasion concomitantly but also enhances the sensitivity to paclitaxel in PC3 cells. These data suggest a shift of miR-148a function from an onco-miRNA in hormone-sensitive PCa to a tumor suppressor in hormone-resistant PCa. 15 MiR-221 and miR-222 Upregulation of both miR-221 and miR-222 has been reported in several types of tumors including PCa. [116] [117] [118] Recently, NF-kB subunit p65 and c-Jun have been identified to bind at two separate distal regions of the upstream of miR-221/222 promoter. Ectopic modulation of the two transcriptional factors is one of the reasons to account for miR-221/222 overexpression. 119 The aberrant expression of miR-221/222 has been shown to be associated with the development of human CRPC, 120 and their expression are significantly increased in AIPC cell lines along with the reduction of PSA expression compared with ADPC cell lines. 121 Galardi et al. 122 have reported that inhibition of the expression of miR-221/222 induces a G0/G1-phase arrest by upregulating cellcycle inhibitor p27 and reduces the ability of clonogenesis in PC3 cell. Overexpression of miR-221/222 by thrombin 123 blocks p27 expression and in turn upregulates a series of cell-cycle factors such as Skp2, cyclin A and cyclin D1, so as to result in a G1-to-Sphase shift and enhances the colony-forming potential. 124 In addition, GTP-binding RAS-like 3 (DIRAS3, also known as ARHI) is recently identified to be another target of miR-221/222. 125, 126 ARHI is an imprinted tumor suppressor gene whose expression is usually downregulated in cancer. 127 Suppression of miR-221/222 expression significantly induces the expression of ARHI and inhibits PC3 cell growth in vitro. 125, 126 These results indicate that miR-221/222 functions as an onco-miRNA to promote PCa growth by modulating the cell-cycle control. However, recent studies by Fuse et al. 128 indicate a tumor suppressor-like function of miR-222 on regulating the cell-cycle progression in PCa cell lines. They also reported that expression of miR-222, together with miR-205, miR-31 and miR-187, is downregulated in clinical specimens of PCa. These findings may provide a novel viewpoint for the 'role shift' of a given miRNA in a specific cancer.
MiR-125b
As an androgen-inducible miRNA, 20 upregulation of miR-125b in ADPC cell line LNCaP stimulates its growth and malignance and renders these cells to be resistant to androgen withdrawal. 129 Forced expression of synthetic miR-125b in AIPC cells promotes cell proliferation via repressing the expression of Bak1, a pro-apoptotic gene. 130 In addition to Bak1, other two proapoptotic genes p53 and Puma are found as a target of miR125b. 131 Overexpression of miR-125b in LNCaP cells markedly decreases the expressional level of p53 as well as its direct effector Puma, while inhibition of miR-125b activity sensitizes PCa cells to various therapeutic interventions. 131 These results suggest that miR-125b works as an oncogene via anti-apoptosis and is a potentially attractive therapeutic target for the treatment of PCa.
Other oncogenic miRNAs in regulation of PCa MiR-106b is previously shown to be upregulated in PCa and is involved in p21 activation. Inhibition of its expression promotes p21-activated cell-cycle arrest, while forced expression of its precursor overrides radiation-induced p21 activation and G2/M arrest. 132 Recent studies demonstrate that miR-106b directly target caspase-7, a key component in apoptosis pathway, and is associated with early disease recurrence. 133 MiR-106b also represses the expression of transcriptional repressor ZBTB4 and reversely upregulates the specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4, whose overexpression is detected in PCa cell lines. 134 MiR-27a is lately reported as an androgen-regulated oncogenic miRNA in PCa. By AR binding to its promoter, androgen regulates miR-27a expression and accelerates its maturation. MiR-27a is also found to directly target Prohibitin (PHB), a tumor suppressor and AR corepressor. 135 MiR-153 is reported to directly regulate PTEN expression and promote cell-cycle transition and cell proliferation through activating the AKT pathway and downregulating fork head box protein O1 (FOXO1) transcriptional activity. 136 
MIRNAS AND PCA STEM CELLS
It is considered that a tumor mass contains variant population of cells with different characteristics in terms of differentiation status 137 and usually consists of fully differentiated cells in outside regions but progenitor or stem-like cells in center regions. 138 These stem-like cells are a small subpopulation that behave differently as compared with other tumor cells within the same tumor mass and might be responsible for tumor initiation, therapeutic resistance and tumor metastasis and are termed as cancer stem cells (CSC). 138 MiRNAs are emerging as important regulators for the acquisition of cancer stem-like cell features during tumor progression. 139 Increasing evidences suggest that PCa stem cells (PCSC) may possess EMT features, which is closely microRNAs in prostate cancer Y-X Fang and W-Q Gao linked with the recurrence, therapy insensitivity and metastasis of PCa. 28, 140 Recent studies support the notion that specific miRNAs are involved in the regulation of PCSC.
MiR-34a
Recently, Liu et al. 141 have identified miR-34a, together with let-7b, to be commonly downregulated in CD44 þ populations from the LAPC9, LAPC4 and DU145 tumors, CD133 þ populations from LAPC4 tumors and a2b1 þ populations from Du145 tumors, respectively. In previous reports, CD44 þ and CD44 þ a2b1 þ populations are shown to be associated with the high tumor-initiating and metastatic potential of PCSC. 142, 143 In addition, CD133 þ /CD44 þ /a2b1 þ populations exhibit an enhanced clonogenic potential in PCa. 144 Based on these results, Liu et al. 141 proposed a hypothesis that miR-34a is involved in the regulation of PCSC and metastasis. They have further demonstrated that overexpression of miR-34a in purified CD44 þ cell significantly inhibits the tumor growth and metastasis in vivo. In contrast, neutralization of endogenous miR-34a promotes tumor regeneration and metastasis. Furthermore, miR-34a suppresses PCSC properties by inhibiting prostasphere establishment, migration and invasiveness of CD44 þ PCa cells, and directly regulates the expression of CD44 at a post-transcriptional level as there are two miR-34a target sites located in the 3 0 UTR of CD44. Besides CD44, miR-34a is also found to regulate self-renewal capacity of PCSC through targeting AR and Notch-1 signaling, both of which are critically involved with growth and metastasis of PCa. 145 Moreover, systemic delivery of miR-34a inhibits metastasis from the prostate to the lung and other organs in mice bearing orthotopic human PCa, suggesting a therapeutic potential of miR-34a. 141 Let-7 family Let-7 family has been known well to be involved not only in the regulation of cell transformation and progression 146 but also in the acquisition of the characteristics of cancer stem-like cells. 147 Recently, Kong et al. 148 found that in PCa cells displaying stem-like cell features, the expression of miR-200 and/or let-7 family is decreased. Restoration of miR-200 inhibits the growth of PCa cells that possess EMT features and represses the expression of Notch-1 and Lin28B. The repression of Lin28B subsequently increases expression of let-7 and inhibits self-renewal in PCa cells. Upregulation of let-7 suppresses the expression of EZH2, a putative target of let-7 family, which is demonstrated to control the stem cell function. 149 Overexpression of EZH2 has been strongly linked with cancer progression partly through promoting EMT in cancer cell, a phenomenon which is reminiscent for cancer stem cells. 150 Ectopic expression of let-7 could repress its expression at a post-transcriptional level by binding with its 3 0 UTR. 149 Consistent with this notion in PCa stem/progenitor cell populations that express CD44 þ , CD133 þ and integrin a2b1 þ , both let-7 and miR-34a expressions are downregulated. Overexpression of either let-7 or miR-34a can inhibit PCa cell proliferation and tumor recurrence by different mechanisms. MiR-34a inhibits cell proliferation by inducing G1-phase cell-cycle arrest accompanied with cell senescence, while let-7 exerts its effects by inducing G2-M-phase cell-cycle arrest without senescence. 151 All these results indicate an important role of let-7 in regulation of PCSC function and a potential application of let-7 for treatment of PCSC.
MiR-145
Recent studies have shown that miR-145 participates in the regulation of cell apoptosis, proliferation as well as neural development and stem cell differentiation. Its function on regulation of pluripotency in human embryonic stem cells (hESC) and its direct link to pluripotency gene expression were first revealed in 2009. 152 It is shown that miR-145 directly regulates pluripotency factors OCT4, SOX2 and KLF4 by targeting their 3 0 UTRs, respectively. Meanwhile, the transcription of miR-145 is repressed by OCT4, which uncovers a double-negative feedback loop between the factors and miR-145. 152 Yamaguchi et al. 153 have further demonstrated that via targeting KLF4 and 5, miR-145 Other miRNAs in regulation of PCSC MiR-320 and miR-708 are found to be associated with the acquisition of characteristics of PCSC. 159, 160 MiR-320 is downregulated in PCa and overexpression of miR-320 significantly decreases the expression of Wnt/b-catenin pathway by directly targeting b-catenin. In CD44-high subpopulation of PCa, overexpression of miR-320 suppresses while underexpression of miR-320 increases the cancer stem-like properties. 159 MiR-708 is found to directly regulate CD44 and AKT expression in PCa. Restoring miR-708 leads to decreased tumorigenesis in CD44 þ PCa-initiating cells. Lower miR-708 expression is also tightly associated with recurrence and poorer survival outcome in PCa patients clinically. 160 Circulating miRNAs as biomarkers in PCa Lawrie et al. 161 first reports the existence of circulating miRNAs in serum. Recently, it has been indicated that circulating miRNAs are promising and practicable biomarkers for noninvasive diagnosis and prognosis in various tumors including PCa. 162 MiR-141 is one of the well-reported circulating miRNAs, whose serum level is significantly higher in patients with PCa than in healthy controls. 163, 164 It is demonstrated that miR-141 has a similar effect on predicting clinical progression with other clinically validated biomarkers in PCa such as lactate dehydrogenase and PSA. 165 Further studies reveal that miR-141 and miR-375 are associated with metastatic PCa when evaluated by serum samples while miR-107 and miR-574-3p by urine samples. 166 Moreover, miR-141, miR-375 and miR-378* are found overexpressed, while miR-409-3p underexpressed in serum from CRPC patients Figure 4 . MiRNAs participate in regulation of PCa initiation, carcinogenesis and metastasis. MiRNAs, act as either tumor suppressors or oncogenes. They play roles at one particular stage or multiple stages of PCa progression including acquisition of PCSCs, tumor proliferation and invasion and metastasis. HRPC, hormone-refractory PCa; HSPC, hormone-sensitive PCa.
microRNAs in prostate cancer Y-X Fang and W-Q Gao compared with those with low-risk, localized tumors. 167 A mouse model of human PCa also validates miR-141, miR-375 along with miR-298 and miR-346 as promising serum markers for diagnosis. 168 Studies on mechanisms further indicate that miR-141 works as an oncogenic miRNA in PCa by targeting an orphan receptor small heterodimer partner (Shp), a corepressor of AR, and increasing the transcriptional activity of AR. 169 MiR-21 is another serum miRNA that can be combined with miR-141 and PSA as comarkers for elevating the positive predicting value in PCa patients. 170 Its serum level appears to be correlated with the level of PSA in both ADPC and HRPC (hormone-refractory PCa) patients and higher in docetaxelresistant patients. 171 By evaluating the levels of miR-21, miR-141 and miR-221 in serum, miR-21 and miR-221, but not miR-141, are found significantly higher in PCa patients, which indicate a varying pattern of the three circulating miRNAs in various clinical subgroups of PCa. 172 Although miR-21 is a potentially novel marker for risk assessment, recurrence prediction and a therapeutic target for PCa, 173, 174 the validity of these applications remains to be determined. 175 Regulation of miRNAs in PCa The pattern of miRNA regulation in PCa can be summarized as 'a single miRNA can target several mRNAs and several miRNAs may coregulate one mRNA' (Figure 3) . First, one miRNA can target 'multiple' genes, which are grouped in a specific pathway or functionally related. This regulatory pattern was first reported in Drosophila and has also been uncovered in humans. 176 Here in this review, we have discussed about a series of miRNAs, their multiple targets and their functions in PCa. Second, expression of a given gene can be regulated by 'multiple' miRNAs at a posttranscriptional level. 177 In PCa, for instance, (i) AR can be regulated by 410 miRNAs including let-7c, miR-34a, miR-34c, miR-31 and miR-124; 39, 72, 93, 94, 145, 178 (ii) BTG2 can be regulated by miR-21, miR-32 and miR-148a; 16, 109 (iii) CD44 can be regulated by miR-34a and miR-708. 141, 160 Furthermore, given that miRNA regulates mRNA expression through the interaction with MRE in 3 0 UTR, multiple MREs for various miRNAs may mediate miRNAmiRNA interactions during regulations of PCa progression. 179 Third, a double-negative regulatory loop between miRNA and its target has been observed in PCa, such as miR-200/miR-1-Slug loop, let-7 family-Lin28 loop and miR-34b-DNMTs/HDACs loop ( Figure 3 ). In addition, there appears to be a tissue-specific pattern in PCa, in which several miRNAs are androgen-inducible miRNAs ( Figure 1 ) such as miR-21, miR-101, miR-125b, miR-27a and so on. [17] [18] [19] [20] [21] 135 By androgen-dependent recruitment of AR to the ARE region of their promoters, the transcription of these miRNAs are tightly regulated by the androgen and/or AR expressional level. Overexpression or underexpression of these miRNAs due to the dysregulation of AR renders the cells resistant to androgen deprivation in ADPC and stimulates cell proliferation in CRPC.
CONCLUSIONS
Mounting evidences indicate that miRNAs can exert their functions as either tumor suppressors or oncogenes and play an important role in prostatic initiation and progression, including therapeutic resistance, PCSC, EMT and metastasis (Figure 4) . With the identification of more miRNAs that have specific functions in PCa, a more detailed regulatory role of miRNAs will be revealed in tumorigenesis and progression of PCa, which may allow to accurately define the clinical application of specific miRNAs in diagnosis, treatment and prognosis of PCa.
